Korsana Biosciences, Inc.(KRSA)

Biotechnology · Waltham, MA

$31.34+0.62 (+2.02%)

Delayed quote: Oct 6, 2026, 10:09 AM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:12:38.264Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:12:38.264Z.

Quote observation: 2026-10-06T14:09:13.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 146,713,509
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 1,391,000
TTM operating EBITDA · period ending 2026-06-30: -6,824,000

FMP input reference: a391670e5a4a022aad0cee8204cefb21b4613c0a4e77d467850b61b24c11a6b7

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KRSA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

KRSA Competitors' EV/EBITDA Ratio

KRSA

Korsana Biosciences, Inc.

Current

Market Cap

$146.71M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABOS

Acumen Pharmaceuticals, Inc.

vs KRSA

Market Cap

$148.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMRX

Immuneering Corporation

vs KRSA

Market Cap

$144.79M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LFMDP

LifeMD, Inc.

vs KRSA

Market Cap

$142.72M

EV/EBITDA Ratio

N/A

TTM Avg

159.13x

3Y Avg

159.13x

5Y Avg

159.13x

CRDL

Cardiol Therapeutics Inc.

vs KRSA

Market Cap

$151.58M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FBIOP

Fortress Biotech, Inc.

vs KRSA

Market Cap

$141.70M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDXS

Codexis, Inc.

vs KRSA

Market Cap

$152.74M

EV/EBITDA Ratio

N/A

TTM Avg

183.85x

3Y Avg

184.46x

5Y Avg

184.46x

ACOG

Alpha Cognition Inc

vs KRSA

Market Cap

$140.09M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AIRS

AirSculpt Technologies, Inc.

vs KRSA

Market Cap

$139.95M

EV/EBITDA Ratio

450.81x

TTM Avg

352.35x

3Y Avg

117.66x

5Y Avg

91.76x

FRNM

Freenome, Inc.

vs KRSA

Market Cap

$138.47M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Korsana Biosciences, Inc. (KRSA)	$146.71M	N/A	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$148.07M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$144.79M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMDP)vs ›	$142.72M	N/A	159.13x	159.13x	159.13x
Cardiol Therapeutics Inc. (CRDL)vs ›	$151.58M	N/A	N/A	N/A	N/A
Fortress Biotech, Inc. (FBIOP)vs ›	$141.70M	N/A	N/A	N/A	N/A
Codexis, Inc. (CDXS)vs ›	$152.74M	N/A	183.85x	184.46x	184.46x
Alpha Cognition Inc (ACOG)vs ›	$140.09M	N/A	N/A	N/A	N/A
AirSculpt Technologies, Inc. (AIRS)vs ›	$139.95M	450.81x	352.35x	117.66x	91.76x
Freenome, Inc. (FRNM)vs ›	$138.47M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics